New obesity drug put through safety check with common meds
NCT ID NCT07362030
First seen Jan 25, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-stage study checks how a new experimental drug for obesity, called RAY1225, affects the way the body processes four common medications: warfarin, atorvastatin, metformin, and digoxin. Thirty-two healthy adults will take RAY1225 along with these drugs to see if any dangerous interactions occur. The goal is to gather safety information before testing the drug in larger groups of people with obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dongguan People's Hospital
Dongguan, China
Conditions
Explore the condition pages connected to this study.